UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: ACAD |
| Industry | Biopharmaceutical, Healthcare |
| Founded | 1993 |
| Headquarters | San Diego, CA, U.S. |
|
Key people
|
Stephen R. Davis CEO |
| Products | Pimavanserin |
| Revenue |  $42.13M (2011) |
|
Operating income
|
$22.85M (2011) |
|
Net income
|
$22.76M(2011) |
| Total assets | 108.71M (2012) |
|
Number of employees
|
95 |
| Website | |
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-07 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -0.21 | -0.21 |
| Q1 2022 | 2022-05-04 | -0.33 | -0.33 |
| Q4 2021 | 2022-02-28 | -0.27 | -0.27 |
| Q3 2021 | 2021-11-08 | -0.09 | -0.09 |
| Q2 2021 | 2021-08-04 | -0.27 | -0.27 |
| Q1 2021 | 2021-05-05 | -0.42 | -0.42 |
| Q4 2020 | 2021-02-24 | -0.42 | -0.42 |
| Q3 2020 | 2020-10-21 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-05 | -0.27 | -0.27 |
| 2016-07-08 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $44.00 |
| 2016-06-22 | Downgrade | Bank of America | Buy to Neutral | $40.00 |
| 2016-06-22 | Downgrade | Bank of America Corp. | Buy to Neutral | $40.00 |
| 2016-05-22 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-19 | Reiterated Rating | Piper Jaffray | Positive | $44.00 |
| 2016-05-19 | Reiterated Rating | Piper Jaffray Cos. | Positive | $44.00 |
| 2016-05-06 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-05-05 | Reiterated Rating | Piper Jaffray | Overweight | $44.00 |
| 2016-05-05 | Reiterated Rating | Cowen and Company | Outperform | $41.00 |
| 2016-05-03 | Downgrade | Leerink Partner | Outperform to Market Perform | |
| 2016-05-03 | Downgrade | Leerink Swann | Outperform to Market Perform | $40.00 to $35.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-01 | Reiterated Rating | Aegis | Buy | $54.00 |
| 2016-03-31 | Reiterated Rating | Needham & Company LLC | Buy | $49.00 |
| 2016-03-30 | Boost Price Target | Piper Jaffray | Overweight | $39.00 to $44.00 |
| 2016-03-28 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2016-03-28 | Reiterated Rating | Bank of America | Buy | |
| 2016-03-28 | Reiterated Rating | Leerink Swann | Outperform | $40.00 |
| 2016-03-28 | Reiterated Rating | HC Wainwright | Buy | $50.00 |
| 2016-03-27 | Reiterated Rating | Piper Jaffray | Buy | $39.00 to $44.00 |
| 2016-03-22 | Reiterated Rating | JMP Securities | Outperform | $43.00 |
| 2016-03-15 | Reiterated Rating | Needham & Company LLC | Buy | $49.00 |
| 2016-03-02 | Reiterated Rating | Leerink Swann | Buy | $40.00 |
| 2016-02-24 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $75.00 to $61.00 |
| 2016-02-08 | Initiated Coverage | Bank of America | Buy | $40.00 |
| 2016-01-26 | Reiterated Rating | Aegis | Buy | |
| 2016-01-22 | Upgrade | Piper Jaffray | Neutral to Overweight | $39.00 |
| 2015-12-15 | Reiterated Rating | Leerink Swann | Outperform | $52.00 to $47.00 |
| 2015-11-07 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-11-06 | Reiterated Rating | Cowen and Company | Buy | $50.00 |
| 2015-11-06 | Boost Price Target | Leerink Swann | Outperform | $48.00 to $52.00 |
| 2015-11-06 | Downgrade | Piper Jaffray | Overweight to Hold | $48.00 to $39.00 |
| 2015-09-16 | Initiated Coverage | JPMorgan Chase & Co. | Hold | |
| 2015-09-04 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $55.00 |
| 2015-09-03 | Reiterated Rating | Needham & Company LLC | Buy | $49.00 |
| 2015-09-01 | Initiated Coverage | Leerink Swann | Buy | |
| 2015-08-28 | Reiterated Rating | Cowen and Company | Buy | $50.00 |
| 2015-08-27 | Upgrade | Piper Jaffray | Neutral to Overweight | $48.00 |
| 2015-08-25 | Initiated Coverage | Aegis | Buy | $54.00 |
| 2015-08-07 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $45.00 to $55.00 |
| 2015-08-07 | Reiterated Rating | Cowen and Company | Outperform | $43.00 to $50.00 |
| 2015-08-07 | Boost Price Target | Needham & Company LLC | Buy | $38.00 to $49.00 |
| 2015-08-07 | Downgrade | Piper Jaffray | Overweight to Neutral | $39.00 to $48.00 |
| 2015-07-02 | Reiterated Rating | HC Wainwright | Buy | $50.00 |
| 2015-05-08 | Set Price Target | Needham & Company LLC | Buy | $38.00 |
| 2015-05-08 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $40.00 to $45.00 |
| 2015-04-16 | Initiated Coverage | Leerink Swann | Outperform | $48.00 |
| 2015-03-12 | Reiterated Rating | Piper Jaffray | Overweight | $39.00 |
| 2015-03-12 | Lower Price Target | Jefferies Group | Buy | $50.00 to $47.00 |
| 2015-03-12 | Lower Price Target | Needham & Company LLC | Buy | $40.00 to $38.00 |
| 2015-03-10 | Reiterated Rating | HC Wainwright | Buy | |
| 2015-02-27 | Reiterated Rating | Needham & Company LLC | Buy | $40.00 |
| 2015-02-27 | Boost Price Target | JMP Securities | Outperform | $31.00 to $50.00 |
| 2015-02-24 | Initiated Coverage | HC Wainwright | Buy | $50.00 |
| 2015-02-06 | Reiterated Rating | Roth Capital | Buy | $42.00 |
| 2015-01-28 | Boost Price Target | Jefferies Group | Buy | $42.00 to $50.00 |
| 2014-12-22 | Boost Price Target | Needham & Company LLC | Buy | $26.00 to $40.00 |
| 2014-11-21 | Initiated Coverage | Cowen and Company | Outperform | $46.00 |
| 2014-05-15 | Initiated Coverage | Morgan Joseph | Overweight | |
| 2014-05-15 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $33.00 |
| 2014-03-04 | Boost Price Target | Jefferies Group | $26.00 to $38.00 | |
| 2013-10-07 | Initiated Coverage | Ned Davis Research | Neutral | |
| 2013-08-07 | Reiterated | Ladenburg Thalmann | Buy | $15 to $24 |
| 2013-08-07 | Downgrade | MLV & Co | Buy to Hold | $18 to $20 |
| 2013-04-11 | Reiterated | Needham | Buy | $9 to $16 |
| 2013-04-11 | Reiterated | MLV & Co | Buy | $12.50 to $18 |
| 2013-04-11 | Reiterated | Ladenburg Thalmann | Buy | $9 to $15 |
| 2013-03-13 | Reiterated | Ladenburg Thalmann | Buy | $8 to $9 |
| 2012-11-28 | Reiterated | MLV & Co | Buy | $4.50 to $8.50 |
| 2012-11-27 | Reiterated | Ladenburg Thalmann | Buy | $8 |
| 2012-04-30 | Initiated | Ladenburg Thalmann | Buy | |
| 2009-09-01 | Downgrade | Citigroup | Hold to Sell | |
| 2009-05-05 | Upgrade | JMP Securities | Mkt Perform to Mkt Outperform | $7 |
| 2008-07-08 | Upgrade | Banc of America Sec | Sell to Neutral | |
| 2008-06-17 | Downgrade | Jefferies & Co | Buy to Hold | $14 to $4 |
| 2008-06-17 | Downgrade | Friedman Billings | Outperform to Mkt Perform | $21 to $8 |
| 2008-06-17 | Downgrade | Banc of America Sec | Buy to Sell | |
| 2008-05-06 | Reiterated | Brean Murray | Sell | $7 to $6 |
| 2008-03-07 | Reiterated | Fortis Bank | Buy | $22 to $23 |
| 2016-07-08 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $44.00 |
| 2016-06-22 | Downgrade | Bank of America | Buy to Neutral | $40.00 |
| 2016-06-22 | Downgrade | Bank of America Corp. | Buy to Neutral | $40.00 |
| 2016-05-22 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-19 | Reiterated Rating | Piper Jaffray | Positive | $44.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ACAD 176 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BAKER BROS. ADVISORS LP | 41.92M |
| Vanguard Group, Inc | 12.93M |
| FMR LLC | 11.57M |
| BlackRock Inc. | 9.97M |
| STATE STREET CORP | 6.78M |
| EcoR1 Capital, LLC | 5.99M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.89M |
| D. E. Shaw & Co., Inc. | 4.71M |
| RTW INVESTMENTS, LLC | 3.67M |
| OPPENHEIMER FUNDS INC | 3.64M |
| JANUS CAPITAL MANAGEMENT LLC | 3.42M |
| MORGAN STANLEY | 3.07M |
| FIRST TRUST ADVISORS LP | 2.92M |
| BlackRock Fund Advisors | 2.70M |
| BlackRock Institutional Trust Company, N.A. | 2.40M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| 14159, L.P. | 20.39% (20278008) | ACAD / |
| BAKER BROS. ADVISORS LP | 0.49% (489977) | ACAD / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA / |
| BAKER FELIX | 0.44% (440802) | ACAD / BCRX / GEVA / GHDX / MRTX / SGEN / |
| GRAY MARY ANN | 0.15% (149476) | ACAD / CBRX / DYAX / GALE / SNMX / TELK / TLOG / |
| Hacksell Uli CEO | 0.12% (115549) | ACAD / |
| Baity Glenn VP AND GC | 0.08% (83734) | ACAD / |
| Iversen Leslie L | 0.04% (36127) | ACAD / |
| Mills Roger EXEC VP | 0.02% (18550) | ACAD / |
| KAPLAN LESTER J PH D | 0.02% (17000) | ACAD / |
| SOLAND DANIEL B | 0.01% (10000) | ACAD / VPHM / |
| Moore Terrence O EVP, CHIEF COMMERCIAL OFFICER | 0.01% (9527) | ACAD / TSPT / |
| Rasmussen Torsten | 0.01% (8500) | ACAD / |
UM